GlassScriptPhysician profile
Sam N Benson
NPI 1265859516
$1,564.94
in general payments reported to CMS, 2019-2025
24 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.15 · 2022: $109 · 2023: $203 · 2024: $101 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $263.83 | 2022-2025 | Farxiga, Airsupra |
| Pfizer INC. | $203.17 | 2023-2025 | |
| Astellas Pharma US INC | $159.11 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $156.70 | 2025 | |
| Abbvie INC. | $106.68 | 2025 | |
| Sumitomo Pharma America, INC. | $75.06 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.87 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $63.29 | 2022-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $59.69 | 2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $54.17 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $51.54 | 2022-2025 | Mounjaro, Zepbound |
| Hologic Sales and Service, LLC | $39.32 | 2023 | Aptima |
| Phadia US INC. | $33.49 | 2024-2025 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $28.39 | 2025 | Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.66 | 2025 | Caplyta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $25.00 | 2025 | Symbravo |
| Tactile Systems Technology INC | $24.36 | 2025 | Nimbl, Flexitouch Plus |
| Dexcom, INC. | $23.56 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $19.29 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $19.26 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.15 | 2024 | Xarelto |
| Mallinckrodt Hospital Products INC. | $17.76 | 2022 | |
| Shield Therapeutics INC | $16.40 | 2024 | |
| Amgen INC. | $14.19 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.